Pfizer Inc.
PFE and Protalix BioTherapeutics, Inc. PLX
announced today that the Brazilian National Health Surveillance Agency
(ANVISA, Agencia Nacional de Vigilancia Sanitaria) has granted regulatory
approval to UPLYSO™ (alfataliglicerase) for the long-term enzyme replacement
therapy for adults with a confirmed diagnosis of Type I Gaucher disease.
Gaucher disease is a rare lysosomal storage disorder that affects
approximately 10,000 people worldwide.
UPLYSO is known as ELELYSO™ (taliglucerase alfa) outside of Latin America.
ELELYSO was approved by the United States Food and Drug Administration in May
2012 and by Israel's Ministry of Health in September 2012 for the long-term
enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type
I Gaucher disease. The ANVISA approval comes after the approval of UPLYSO by
the Ministry of Public Health in Uruguay in November 2012.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in